EP3110455A4 - Traitement des lésions résistantes - Google Patents

Traitement des lésions résistantes Download PDF

Info

Publication number
EP3110455A4
EP3110455A4 EP15755058.3A EP15755058A EP3110455A4 EP 3110455 A4 EP3110455 A4 EP 3110455A4 EP 15755058 A EP15755058 A EP 15755058A EP 3110455 A4 EP3110455 A4 EP 3110455A4
Authority
EP
European Patent Office
Prior art keywords
treatment
resistant lesions
lesions
resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15755058.3A
Other languages
German (de)
English (en)
Other versions
EP3110455A2 (fr
Inventor
Anthony Phillips
Scott BANNAN
Grove MATSUOKA
Bradford DUFT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocunexus Therapeutics Inc
Original Assignee
CoDa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CoDa Therapeutics Inc filed Critical CoDa Therapeutics Inc
Publication of EP3110455A2 publication Critical patent/EP3110455A2/fr
Publication of EP3110455A4 publication Critical patent/EP3110455A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP15755058.3A 2014-02-25 2015-02-25 Traitement des lésions résistantes Withdrawn EP3110455A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461944566P 2014-02-25 2014-02-25
PCT/US2015/017595 WO2015130840A2 (fr) 2014-02-25 2015-02-25 Traitement des lésions résistantes

Publications (2)

Publication Number Publication Date
EP3110455A2 EP3110455A2 (fr) 2017-01-04
EP3110455A4 true EP3110455A4 (fr) 2017-10-11

Family

ID=54009775

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15755058.3A Withdrawn EP3110455A4 (fr) 2014-02-25 2015-02-25 Traitement des lésions résistantes

Country Status (3)

Country Link
EP (1) EP3110455A4 (fr)
CA (1) CA2940648A1 (fr)
WO (1) WO2015130840A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12054724B2 (en) 2018-04-10 2024-08-06 President And Fellows Of Harvard College AAV vectors encoding clarin-1 or GJB2 and uses thereof
CA3153133A1 (fr) * 2019-09-30 2021-04-08 Chris Bartolome Systemes a base de virus adeno-associe (aav) pour le traitement de la perte auditive genetique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009075882A2 (fr) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Compositions et traitements pour la guérison de blessures aggravées
WO2014145342A2 (fr) * 2013-03-15 2014-09-18 Coda Therapeutics, Inc. Compositions et traitements améliorés pour le soin d'une plaie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044409A1 (fr) * 1999-01-27 2000-08-03 University College London Formulations comportant des nucleotides anti-sens de connexine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009075882A2 (fr) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Compositions et traitements pour la guérison de blessures aggravées
WO2014145342A2 (fr) * 2013-03-15 2014-09-18 Coda Therapeutics, Inc. Compositions et traitements améliorés pour le soin d'une plaie

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAVID L. BECKER ET AL.: "Connexins in wound healing; perspectives in diabetic patients", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - BIOMEMBRANES, vol. 1818, no. 8, 1 August 2012 (2012-08-01), AMSTERDAM, NL, pages 2068 - 2075, XP055307471, ISSN: 0005-2736, DOI: 10.1016/j.bbamem.2011.11.017 *
JOHANNA M. BRANDNER ET AL.: "Connexins 26, 30, and 43: Differences Among Spontaneous, Chronic, and Accelerated Human Wound Healing", 1 May 2004 (2004-05-01), XP055402063, Retrieved from the Internet <URL:http://ac.els-cdn.com/S0022202X15308010/1-s2.0-S0022202X15308010-main.pdf?_tid=93f36308-8cba-11e7-9b03-00000aab0f26&acdnat=1504012043_813c67923de0c385013b5614ac11fb7b> [retrieved on 20170829] *
MENDOZA-NARANJO ARIADNA ET AL.: "Targeting Cx43 and N-Cadherin, which are abnormally upregulated in Venous Leg Ulcers, influences migration, adhesion and activation of Rho GTPases", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 7, no. 5, 1 May 2012 (2012-05-01), pages e37374 - 1, XP002712338, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0037374 *

Also Published As

Publication number Publication date
EP3110455A2 (fr) 2017-01-04
CA2940648A1 (fr) 2015-09-03
WO2015130840A2 (fr) 2015-09-03
WO2015130840A3 (fr) 2015-11-05

Similar Documents

Publication Publication Date Title
EP3212233A4 (fr) Thérapie combinée pour le traitement d&#39;une maladie
EP3072436A4 (fr) Endoscope
EP3078318A4 (fr) Endoscope
EP3134436A4 (fr) Traitement de tumeurs provoquées par h-ras
EP3097843A4 (fr) Endoscope
EP3047788A4 (fr) Endoscope
EP3157565A4 (fr) Traitement d&#39;infections polybactériennes
EP3104880A4 (fr) Procédés améliorés pour le traitement de cancers liés à la vascularisation
EP3050488A4 (fr) Endoscope
EP3183240A4 (fr) Traitement de pathologies articulaires
EP3175768A4 (fr) Endoscope
EP3189333A4 (fr) Diagnostic du cancer
EP3205253A4 (fr) Endoscope
EP3092940A4 (fr) Endoscope
EP3106097A4 (fr) Instrument de traitement
EP3138467A4 (fr) Endoscope
EP3145931A4 (fr) Traitement d&#39;une maladie auto-immune
EP3096752A4 (fr) Traitement d&#39;une néoplasie
EP3231347A4 (fr) Endoscope
EP3158912A4 (fr) Endoscope
EP3125937A4 (fr) Traitement du cancer gastrique
EP3106112A4 (fr) Instrument de traitement
GB201408297D0 (en) Treatment of cancer
EP3189767A4 (fr) Endoscope
EP3130274A4 (fr) Endoscope

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20160923

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170907

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALI20170901BHEP

Ipc: A61K 48/00 20060101AFI20170901BHEP

Ipc: A61P 17/02 20060101ALI20170901BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OCUNEXUS THERAPEUTICS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OCUNEXUS THERAPEUTICS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180407